| Identification | Back Directory | [Name]
Cdk2/9 Inhibitor | [CAS]
507487-89-0 | [Synonyms]
Cdk2/9 Inhibitor
Inhibitor,Nek1,CDK,CK-7,Cdk9,CK 7,kidney development,CK7,inhibit,Cyclin dependent kinase,Cdk2 | [Molecular Formula]
C14H12N6O2S | [MDL Number]
MFCD14585803 | [MOL File]
507487-89-0.mol | [Molecular Weight]
328.35 |
| Chemical Properties | Back Directory | [Boiling point ]
590.5±60.0 °C(Predicted) | [density ]
1.490±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 12.5 mg/mL (38.07 mM; ultrasonic and warming and heat to 60°C) | [form ]
Solid | [pka]
2.99±0.10(Predicted) | [color ]
Light yellow to yellow | [InChI]
1S/C14H12N6O2S/c1-8-12(23-13(15)17-8)11-5-6-16-14(19-11)18-9-3-2-4-10(7-9)20(21)22/h2-7H,1H3,(H2,15,17)(H,16,18,19) | [InChIKey]
DYTKVFHLKPDNRW-UHFFFAOYSA-N |
| Hazard Information | Back Directory | [Uses]
CDK2/9 Inhibitor has been characterized in complex with a variety of inhibitors, but the majority of structures solved are in the inactive form. Research suggests that monomeric CDK2 conformation can be selectively inhibited. | [Biological Activity]
Cell permeable: yes', 'Primary Target
Cdk2/E and Cdk9/T1', 'Product competes with ATP.', 'Reversible: no', 'Target Ki: 2 nM and 4 nM against Cdk2/E and Cdk9/T1, respectively | [IC 50]
NEK1; CDK2; CDK9 |
|
| Company Name: |
Bide Pharmatech Ltd.
|
| Telephone: |
400-1647117 13681763483 |
| Website: |
https://www.bidepharm.com/ |
|